Application of Palliative Hemostatic Radiotherapy in Canine Unresectable Oral Melanoma: A Case Report.

Animals (Basel)

Department of Veterinary Medical Imaging, College of Veterinary Medicine, Konkuk University, Seoul 05029, Republic of Korea.

Published: June 2024

A 9-year-old castrated male Schnauzer dog, weighing 11.6 kg, presented with a persistent hemorrhagic oral mass. An oral examination revealed a right maxillary oral mass characterized by continuous bleeding, halitosis, and severe pain. A cytological examination led to a provisional diagnosis of malignant melanoma, and, despite the option of aggressive surgery, the owner declined. The blood analysis indicated severe hemorrhagic anemia (hematocrit, 18.2%) requiring a blood transfusion. The patient underwent volumetric modulated arc therapy (VMAT) as part of a palliative radiation protocol, receiving six fractions of 6 Gy weekly for hemostasis and clinical improvement. The hemorrhaging ceased after the second fraction, with a subsequent rise in the hematocrit levels and the resolution of the anemia. Additionally, the intake increased following the second fraction, and effective pain management was achieved in the fourth fraction. Following the last fraction, computed tomography revealed a 20% reduction in the tumor size. This case highlights the potential use of radiotherapy for hemostasis in cases of inoperable hemorrhagic oral melanoma and represents the first report on the application of hemostatic radiotherapy in dogs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200987PMC
http://dx.doi.org/10.3390/ani14121746DOI Listing

Publication Analysis

Top Keywords

hemostatic radiotherapy
8
oral melanoma
8
hemorrhagic oral
8
oral mass
8
second fraction
8
oral
5
application palliative
4
palliative hemostatic
4
radiotherapy canine
4
canine unresectable
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!